{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:19:03Z","timestamp":1774264743653,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.bcp.2013.02.025","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T12:05:45Z","timestamp":1362571545000},"page":"1441-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition"],"prefix":"10.1016","volume":"85","author":[{"given":"Un-Jung","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hee","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Kyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Youl","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Nyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2013.02.025_bib0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2013.02.025_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2013.02.025_bib0015","first-page":"420","article-title":"Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells","volume":"1","author":"Yang","year":"2003","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bcp.2013.02.025_bib0020","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1158\/1078-0432.CCR-08-2372","article-title":"Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells","volume":"15","author":"Li","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2013.02.025_bib0025","first-page":"3352","article-title":"Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin","volume":"5","author":"Abolhoda","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2013.02.025_bib0030","first-page":"182","article-title":"Dissecting lipid raft facilitated cell signaling pathways in cancer","volume":"1785","author":"Patra","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2013.02.025_bib0035","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1476-5381.2010.00768.x","article-title":"Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt","volume":"160","author":"Park","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/path.2531","article-title":"Cholesterol depletion induces anoikis-like apoptosis via FAK down-regulation and caveolae internalization","volume":"218","author":"Park","year":"2009","journal-title":"J Pathol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0045","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2353\/ajpath.2006.050959","article-title":"Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents","volume":"168","author":"Li","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/epr.11.2","article-title":"Lipid rafts: signaling and sorting platforms of cells and their roles in cancer","volume":"8","author":"Staubach","year":"2011","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.bcp.2013.02.025_bib0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.taap.2012.01.007","article-title":"Lipid raft: a floating island of death or survival","volume":"259","author":"George","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1937-6448(10)82003-9","article-title":"Lipid rafts, caveolae, and their endocytosis","volume":"282","author":"Lajoie","year":"2010","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0065","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbamcr.2005.05.005","article-title":"Growth factor receptors lipid rafts and caveolae: an evolving story","volume":"1746","author":"Pike","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2013.02.025_bib0070","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00018-005-5554-9","article-title":"P-glycoprotein and \u2018lipid rafts\u2019: some ambiguous mutual relationships (floating on them, building them or meeting them by chance?)","volume":"63","author":"Orlowski","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bcp.2013.02.025_bib0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejps.2008.04.005","article-title":"P-glycoprotein inhibition by membrane cholesterol modulation","volume":"34","author":"Fenyvesi","year":"2008","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bcp.2013.02.025_bib0080","doi-asserted-by":"crossref","first-page":"32380","DOI":"10.1074\/jbc.273.49.32380","article-title":"Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells","volume":"273","author":"Lavie","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.02.025_bib0085","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1023\/A:1008980200583","article-title":"The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence","volume":"11","author":"Shin","year":"2000","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.bcp.2013.02.025_bib0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1749-8546-2-6","article-title":"Pharmacogenomics and the Yin\/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides","volume":"2","author":"Yue","year":"2007","journal-title":"Chin Med"},{"key":"10.1016\/j.bcp.2013.02.025_bib0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-001-1137-y","article-title":"Selective toxicity of ginsenoside Rg3 on multidrug resistant cells by membrane fluidity modulation","volume":"31","author":"Kwon","year":"2008","journal-title":"Arch Pharmacal Res"},{"key":"10.1016\/j.bcp.2013.02.025_bib0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1476-5381.2011.01505.x","article-title":"Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7\/Adr cells","volume":"165","author":"Zhang","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00001813-199102000-00009","article-title":"Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo","volume":"2","author":"Kikuchi","year":"1991","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bcp.2013.02.025_bib0110","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1248\/bpb.31.1802","article-title":"Anti-metastatic potential of ginsenoside Rp1, a novel ginsenoside derivative","volume":"31","author":"Park","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bcp.2013.02.025_bib0115","first-page":"381","article-title":"Molecular mechanisms of ginsenoside Rp1-mediated growth arrest and apoptosis","volume":"24","author":"Kumar","year":"2009","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bcp.2013.02.025_bib0120","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1074\/jbc.275.11.7481","article-title":"Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1 Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status","volume":"275","author":"Kim","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.02.025_bib0125","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2003-12-4255","article-title":"An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line","volume":"104","author":"Ghetie","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2013.02.025_bib0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2013.02.025_bib0135","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1074\/jbc.M411444200","article-title":"Actinomycin D induces histone gamma-H2AX foci and complex formation of gamma-H2AX with Ku70 and nuclear DNA helicase II","volume":"280","author":"Mischo","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.02.025_bib0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/35036052","article-title":"Lipid rafts and signal transduction","volume":"1","author":"Simons","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s002800050692","article-title":"Methyl-beta-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin","volume":"40","author":"Grosse","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1290\/0502016.1","article-title":"Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells","volume":"41","author":"Kamau","year":"2005","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.bcp.2013.02.025_bib0155","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1124\/mol.104.002329","article-title":"Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells","volume":"66","author":"Troost","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0160","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.bcp.2010.06.023","article-title":"American ginseng: potential structure-function relationship in cancer chemoprevention","volume":"80","author":"Qi","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fphar.2012.00025","article-title":"Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action","volume":"3","author":"Nag","year":"2012","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0170","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1124\/dmd.110.034793","article-title":"et al., 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions","volume":"38","author":"Zhang","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2013.02.025_bib0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00210-005-1080-4","article-title":"Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells","volume":"372","author":"Ehrlichova","year":"2005","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.bcp.2013.02.025_bib0180","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.canlet.2006.01.013","article-title":"A case study in misidentification of cancer cell lines: MCF-7\/AdrR cells (re-designated NCI\/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells","volume":"245","author":"Liscovitch","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bcp.2013.02.025_bib0185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1026553626537","article-title":"Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences","volume":"17","author":"Lavie","year":"2000","journal-title":"Glycoconj J"},{"key":"10.1016\/j.bcp.2013.02.025_bib0190","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"gammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2013.02.025_bib0195","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1535-7163.MCT-10-1043","article-title":"Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282","volume":"10","author":"Sooryakumar","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2013.02.025_bib0200","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.neuropharm.2008.02.019","article-title":"Lipid rafts, cholesterol, and the brain","volume":"55","author":"Korade","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2013.02.025_bib0205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbrc.2006.12.202","article-title":"Coupling between membrane microenvironment and ABC transporter activity","volume":"354","author":"Meyer dos Santos","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2013.02.025_bib0210","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.cji.0000211307.05869.6c","article-title":"Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts","volume":"29","author":"Ghetie","year":"2006","journal-title":"J Immunother"},{"key":"10.1016\/j.bcp.2013.02.025_bib0215","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1593\/neo.10328","article-title":"SRC a century of science brought to the clinic","volume":"12","author":"Aleshin","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2013.02.025_bib0220","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.1158\/0008-5472.CAN-06-4539","article-title":"Lipid raft specific knockdown of SRC family kinase activity inhibits cell adhesion and cell cycle progression of breast cancer cells","volume":"67","author":"Hitosugi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2013.02.025_bib0225","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1158\/0008-5472.CAN-05-1822","article-title":"SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells","volume":"65","author":"George","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2013.02.025_bib0230","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.bbrc.2003.08.012","article-title":"Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line","volume":"309","author":"Pengetnze","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2013.02.025_bib0235","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.20140","article-title":"MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells","volume":"110","author":"Klappe","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bcp.2013.02.025_bib0240","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1476-4598-9-145","article-title":"Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling","volume":"9","author":"Liu","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bcp.2013.02.025_bib0245","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2013.02.025_bib0250","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ijc.27649","article-title":"Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo","volume":"132","author":"Liu","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bcp.2013.02.025_bib0255","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.cdd.4401440","article-title":"Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux","volume":"11","author":"Tainton","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bcp.2013.02.025_bib0260","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.addr.2009.05.006","article-title":"Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines","volume":"61","author":"Greco","year":"2009","journal-title":"Adv Drug Delivery Rev"},{"key":"10.1016\/j.bcp.2013.02.025_bib0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2005.07.002","article-title":"Anticancer therapeutics: \u201cAddictive\u201d targets, multi-targeted drugs, new drug combinations","volume":"8","author":"Broxterman","year":"2005","journal-title":"Drug Resist Updat"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213001482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213001482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T07:33:19Z","timestamp":1539847999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295213001482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0006295213001482"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2013.02.025","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2013.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}